Medicinova Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.26next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| COMBAT-ALS Phase 2b/3 Topline Data Release | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
COMBAT-ALS Phase 2b/3 Trial Enrollment Quarterly234.0Target: 234 (Fully Enrolled)
SEANOBI Expanded Access Program Enrollment Quarterly100.0
Cash and Cash Equivalents Quarterly27.3MTarget: Maintain sufficient runway through key clinical readouts
Watch Items
- COMBAT-ALS Phase 2b/3 Topline Data ReleaseTrigger: Topline data expected by end of 2026Action: Evaluate clinical efficacy (Combined Assessment of Function and Survival) and prepare for potential FDA regulatory submission.
- MN-001 (Tipelukast) Phase 2 Topline Data ReleaseTrigger: Topline data expected in Q3 2026Action: Review change from baseline in liver fat content and serum triglycerides to assess metabolic/fibrotic pipeline potential.
- Cash Burn Rate and Capital RunwayTrigger: Annual burn rate of $12M - $13MAction: Monitor cash runway relative to the H2 2027 projection and assess potential dilution from the $30M standby equity facility or $300M shelf registration.
Research as of 19 Jun 2026